银屑病及其合并症。
Psoriasis and Co-morbidity.
机构信息
Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, USA.
出版信息
Acta Derm Venereol. 2020 Jan 30;100(3):adv00033. doi: 10.2340/00015555-3387.
Abstract
Psoriasis is associated with multiple co-morbid medical conditions. The purpose of this study is to evaluate the relationships between psoriasis and cardiovascular disease, psoriatic arthritis, mental health conditions, and immune-mediated diseases, respectively. A literature search was performed during the study period January 1, 2015 to December 18, 2018. Of 2,499 records identified, 28 met our criteria selection and were included in this review. The relationships between psoriasis and these multiple comorbid disease conditions are discussed and are important to consider when developing the treatment plan and overall management of patients with psoriasis. Early recognition and treatment of comorbid disease conditions is important to help improve the quality of life for these patients.
摘要
银屑病与多种合并症相关。本研究旨在分别评估银屑病与心血管疾病、银屑病关节炎、心理健康状况和免疫介导性疾病之间的关系。本研究的文献检索于 2015 年 1 月 1 日至 2018 年 12 月 18 日期间进行。在确定的 2499 条记录中，有 28 条符合我们的标准选择，并纳入本综述。讨论了银屑病与这些多种合并症疾病之间的关系，在制定银屑病患者的治疗计划和整体管理时需要考虑这些关系。早期识别和治疗合并症对于提高这些患者的生活质量非常重要。
相似文献
1
Psoriasis and Co-morbidity.
Acta Derm Venereol. 2020 Jan 30;100(3):adv00033. doi: 10.2340/00015555-3387.
2
Beyond skin deep: addressing comorbidities in psoriasis.
Med J Aust. 2020 Jun;212(11):528-534. doi: 10.5694/mja2.50591. Epub 2020 May 10.
3
Clinical challenges faced in real-world management of moderate-to-severe psoriasis: a personal view.
G Ital Dermatol Venereol. 2017 Dec;152(6):551-554. doi: 10.23736/S0392-0488.17.05766-2. Epub 2017 Sep 12.
4
Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review.
Int J Mol Sci. 2020 Mar 1;21(5):1690. doi: 10.3390/ijms21051690.
5
Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.
Curr Pharm Des. 2014;20(4):500-12. doi: 10.2174/138161282004140213123505.
6
[Integrated approach to comorbidity in patients with psoriasis.Working Group on Psoriasis-associated Comorbidities].
Actas Dermosifiliogr. 2012 Jan;103 Suppl 1:1-64. doi: 10.1016/S0001-7310(12)70001-7.
7
Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis.
Arthritis Care Res (Hoboken). 2011 Dec;63(12):1729-35. doi: 10.1002/acr.20627.
8
Cardiovascular comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting.
J Rheumatol. 2013 Aug;40(8):1434-7. doi: 10.3899/jrheum.130457.
9
Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 annual meeting.
J Rheumatol. 2011 Mar;38(3):567-71. doi: 10.3899/jrheum.101124.
10
Psoriasis: classical and emerging comorbidities.
An Bras Dermatol. 2015 Jan-Feb;90(1):9-20. doi: 10.1590/abd1806-4841.20153038.
引用本文的文献
1
Characterization of intestinal microbiota in patients with psoriasis combined with metabolic syndrome.
Mol Cell Biochem. 2025 Aug 20. doi: 10.1007/s11010-025-05370-4.
2
Prevalence of Psychiatric and Addictive Disorders in Patients with Psoriasis: A Cross-Sectional Study.
Diagnostics (Basel). 2025 May 14;15(10):1231. doi: 10.3390/diagnostics15101231.
3
Management of Challenging Psoriasis Clinical Scenarios.
Dermatol Ther (Heidelb). 2025 Jun;15(6):1555-1567. doi: 10.1007/s13555-025-01393-3. Epub 2025 Apr 15.
4
The prevalence and risk of allergic rhinitis in psoriasis patients: a systematic review and meta-analysis.
Sci Rep. 2025 Mar 15;15(1):9009. doi: 10.1038/s41598-025-86779-1.
5
Add-on effects of total glucosides of paeony on conventional therapies for psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Front Pharmacol. 2025 Feb 19;16:1527288. doi: 10.3389/fphar.2025.1527288. eCollection 2025.
6
The Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis.
J Clin Med. 2025 Feb 19;14(4):1374. doi: 10.3390/jcm14041374.
7
Association between psoriasis and Life's Essential 8 among adults in the United States.
Arch Dermatol Res. 2025 Feb 22;317(1):465. doi: 10.1007/s00403-025-03845-4.
8
Association of systemic immune-inflammation index (SII) with risk of psoriasis: a cross-sectional analysis of National Health and Nutrition Examination Survey 2011-2014.
Eur J Med Res. 2025 Jan 29;30(1):58. doi: 10.1186/s40001-025-02304-0.
9
The Role of Long Non-Coding RNA in the Pathogenesis of Psoriasis.
Noncoding RNA. 2025 Jan 17;11(1):7. doi: 10.3390/ncrna11010007.
10
The Role of Extracellular Vesicles in the Development and Treatment of Psoriasis: Narrative Review.
Pharmaceutics. 2024 Dec 12;16(12):1586. doi: 10.3390/pharmaceutics16121586.
本文引用的文献
1
Association Between Aortic Vascular Inflammation and Coronary Artery Plaque Characteristics in Psoriasis.
JAMA Cardiol. 2018 Oct 1;3(10):949-956. doi: 10.1001/jamacardio.2018.2769.
2
Echocardiographic evaluation of diastolic dysfunction in young and healthy patients with psoriasis: A case-control study.
Monaldi Arch Chest Dis. 2018 Sep 4;88(3):934. doi: 10.4081/monaldi.2018.934.
3
Mild to moderate psoriasis is associated with oxidative stress, subclinical atherosclerosis, and endothelial dysfunction.
Pol Arch Intern Med. 2018 Aug 31;128(7-8):434-439. doi: 10.20452/pamw.4301. Epub 2018 Jul 27.
4
Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study.
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):128-135. doi: 10.1111/jdv.15159. Epub 2018 Jul 17.
5
Increased risks of autoimmune rheumatic diseases in patients with psoriasis: A nationwide population-based study.
J Am Acad Dermatol. 2018 Oct;79(4):778-781. doi: 10.1016/j.jaad.2018.06.026. Epub 2018 Jun 18.
6
Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.
Circ Cardiovasc Imaging. 2018 Jun;11(6):e007394. doi: 10.1161/CIRCIMAGING.117.007394.
7
Human Leukocyte Antigen-Class I Alleles and the Autoreactive T Cell Response in Psoriasis Pathogenesis.
Front Immunol. 2018 Apr 30;9:954. doi: 10.3389/fimmu.2018.00954. eCollection 2018.
8
Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis.
J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1320-1326. doi: 10.1111/jdv.14951. Epub 2018 May 1.
9
The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study.
J Am Acad Dermatol. 2018 Jul;79(1):60-68. doi: 10.1016/j.jaad.2018.02.050. Epub 2018 Mar 1.
10
Autoimmunity and autoimmune co-morbidities in psoriasis.
Immunology. 2018 May;154(1):21-27. doi: 10.1111/imm.12891. Epub 2018 Feb 6.
Zotero 插件